Chief of Clinical Trials
Division of Hematology/Oncology
Vanderbilt University Medical Center
Brian Rini, MD, FACP, has disclosed that he has received consulting fees from Novartis and Pfizer and he has received research support from Acceleron, Bristol-Myers Squibb, Immatics, Peloton, and Pfizer.
ASCO 2016 promises to reveal exciting clinical data in GU malignancies. I will highlight some of these data with downloadable slidesets and an online activity where I will discuss the clinical implications of the data with Daniel M. Geynisman, MD, after the ASCO annual meeting. Chief among them—and on the heels of the recent FDA approval—are updated data from IMvigor210 investigating the anti–PD-L1 checkpoint inhibitor atezolizumab in advanced urothelial cancer, both in cisplatin-refractory and cisplatin-ineligible patients that will be presented. In addition, predictive biomarker data from these trials are being generated. The anti–PD-1 checkpoint inhibitor nivolumab is now approved in refractory RCC, and phase III data from CheckMate 025 will be presented, as well as a phase III trial comparing nivolumab head to head with everolimus, both evaluating treatment beyond progression, a scenario that we encounter frequently in practice. Finally, data exploring chemotherapy in CRPC with cabazitaxel in the first-line setting and intermittent vs continuous docetaxel, as well as the androgen receptor splice variant AR-V7, a potential predictive marker for novel hormonal therapy, are awaited.
Please join CCO at ASCO 2016 in Chicago for 2 live symposia in GU malignancies: Clinical Application of Immune Checkpoint Inhibitors in bladder cancer and Optimizing the Treatment of Advanced Prostate Cancer: Expert Review of the Latest Data and Guideline Recommendations. After the meeting, follow CCO’s coverage of some of the studies discussed above and other important abstracts with downloadable summary slidesets of key data in GU malignancies presented at ASCO 2016 and an online expert analysis of the data.
What are you most looking forward to at ASCO 2016 in GU malignancies? Please share your thoughts in the comment box below.